Canaccord raised the firm’s price target on Staar Surgical to $32 from $31 and keeps a Hold rating on the shares. The firm said they reported a straightforward Q4, with revenue relatively in line with the company’s preannouncement from January. The company also reiterated the 2024 revenue guidance it provided in January.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
- Is STAA a Buy, Before Earnings?
- Staar Surgical announces strategic pact in U.S. with SharpeVision, no terms
- Staar Surgical price target lowered to $31 from $33 at Canaccord
- Fly Insider: Athira Pharma, Microstrategy among week’s notable insider trades
- Staar Surgical sees FY24 revenue $335M -$340M, consensus $366.8M
